Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization

Yan, Lifeng; Hou, Chenchen; Liu, Juan; Wang, Yi; Zeng, Chenxi; Yu, Jun; Zhou, Tianyu; Zhou, Qing; Duan, Shengzhong; Xiong, Weining

doi:10.1007/s11427-022-2314-8

Cited by 7 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the physiological structure of the lung and nasal cavity, intranasal administration of liposomes exhibits enhanced lung retention compared to intravenous administration, thus nasal inhalation is also an ideal way to improve lung targeting of liposomes (Patlolla et al, 2010). Nasal inhalation fully leverages the advantages of lung gas exchange function, thereby increasing the concentration of drugs deposited in the lungs and achieving higher therapeutic effects with lower drug doses (Figure 4b) (Yan et al, 2023).…”

Section: Application Of Liposomes In Lung Repairmentioning

confidence: 99%

“…(b) PEG‐modified liposomes have attained higher therapeutic effects through nasal administration at lower drug doses (Yan et al, 2023). Reproduced with permission from Yan et al (2023), Copyright 2023, the Author(s). (c) Epidermal growth factor receptor modified liposomes have the ability to target tumor cells in cancer (H. Huang, Yi, et al, 2023).…”

Section: Delivery Of Liposomes To Target Organsmentioning

confidence: 99%

“…Reproduced with permission fromSun et al (2023), Copyright 2023, American Chemical Society. (b) PEGmodified liposomes have attained higher therapeutic effects through nasal administration at lower drug doses(Yan et al, 2023). Reproduced with permission fromYan et al (2023), Copyright 2023, the Author(s).…”

mentioning

confidence: 99%

See 2 more Smart Citations

The application strategy of liposomes in organ targeting therapy

Xun,

Li,

Xue

2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Liposomes—microscopic phospholipid bubbles with bilayered membrane structure—have been a focal point in drug delivery research for the past 30 years. Current liposomes possess a blend of biocompatibility, drug loading efficiency, prolonged circulation and targeted delivery. Tailored liposomes, varying in size, charge, lipid composition, and ratio, have been developed to address diseases in specific organs, thereby enhancing drug circulation, accumulation at lesion sites, intracellular delivery, and treatment efficacy for various organ‐specific diseases. For further successful development of this field, this review summarized liposomal strategies for targeting different organs in series of major human diseases, including widely studied cardiovascular diseases, liver and spleen immune diseases, chronic or acute kidney injury, neurodegenerative diseases, and organ‐specific tumors. It highlights recent advances of liposome‐mediated therapeutic agent delivery for disease intervention and organ rehabilitation, offering practical guidelines for designing organ‐targeted liposomes.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials > Lipid‐Based Structures

show abstract

Section: Application Of Liposomes In Lung Repairmentioning

confidence: 99%

Section: Delivery Of Liposomes To Target Organsmentioning

confidence: 99%

See 1 more Smart Citation

The application strategy of liposomes in organ targeting therapy

Xun,

Li,

Xue

2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“… 106 For example, intratracheal administration of siRNA targeting Plekhf1 with liposome carrier could effectively inhibit Plekhf1 expression levels in the lungs, and this strategy can be used to protect against pulmonary fibrosis disease. 233 …”

Section: Administration Routes For Rna-based Drugsmentioning

confidence: 99%

RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges

Yuan,

Shi,

Lee

2024

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

“…Despite its significance, the assessment of CDKN2A expression levels remains constrained by several limitations. 11 Current detection methods, whether they utilize peripheral blood cytokine assays or are based on fresh or paraffin tissue specimens, are fraught with challenges related to cost, specimen collection, or reliability. There is a pressing need for methodologies that are both accurate and practical in clinical settings, 3 especially given the fundamental role of CDKN2A in HNSCC prognosis.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of CDKN2A in head and neck squamous cell carcinoma via pathomics and machine learning

Wang,

Zhou,

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

This study aims to enhance the prognosis prediction of Head and Neck Squamous Cell Carcinoma (HNSCC) by employing artificial intelligence (AI) to analyse CDKN2A gene expression from pathology images, directly correlating with patient outcomes. Our approach introduces a novel AI‐driven pathomics framework, delineating a more precise relationship between CDKN2A expression and survival rates compared to previous studies. Utilizing 475 HNSCC cases from the TCGA database, we stratified patients into high‐risk and low‐risk groups based on CDKN2A expression thresholds. Through pathomics analysis of 271 cases with available slides, we extracted 465 distinctive features to construct a Gradient Boosting Machine (GBM) model. This model was then employed to compute Pathomics scores (PS), predicting CDKN2A expression levels with validation for accuracy and pathway association analysis. Our study demonstrates a significant correlation between higher CDKN2A expression and improved median overall survival (66.73 months for high expression vs. 42.97 months for low expression, p = 0.013), establishing CDKN2A's prognostic value. The pathomic model exhibited exceptional predictive accuracy (training AUC: 0.806; validation AUC: 0.710) and identified a strong link between higher Pathomics scores and cell cycle activation pathways. Validation through tissue microarray corroborated the predictive capacity of our model. Confirming CDKN2A as a crucial prognostic marker in HNSCC, this study advances the existing literature by implementing an AI‐driven pathomics analysis for gene expression evaluation. This innovative methodology offers a cost‐efficient and non‐invasive alternative to traditional diagnostic procedures, potentially revolutionizing personalized medicine in oncology.

show abstract

Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization

Cited by 7 publications

References 49 publications

The application strategy of liposomes in organ targeting therapy

The application strategy of liposomes in organ targeting therapy

RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges

Prognostic value of CDKN2A in head and neck squamous cell carcinoma via pathomics and machine learning

Contact Info

Product

Resources

About